Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial

References

• Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and. cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323. doi:10.1093/eurheartj/ehz486
   PubMed Web of Science ®Google Scholar
• Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. a consensus report by the American Diabetes Association (ADA) and the European Association for the study of diabetes (EASD). Diabetes Care. 2020;43(2):487–493. doi:10.2337/dci19-0066
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322. doi:10.1056/NEJMoa1603827
   PubMed Web of Science ®Google Scholar
• Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31–39. doi:10.1016/S0140-6736(18)32590-X
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306. doi:10.1056/NEJMoa1811744
   PubMed Web of Science ®Google Scholar
• Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153–165. doi:10.1016/j.cmet.2006.01.004
   PubMed Web of Science ®Google Scholar
• White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–1335. doi:10.1056/NEJMoa1305889
   PubMed Web of Science ®Google Scholar
• Goldshtein I, Karasik A, Melzer-Cohen C, et al. Urinary albumin excretion with sitagliptin compared to sulfonylurea as add on to metformin in type 2 diabetes patients with albuminuria: a real-world evidence study. J Diabetes Complicat. 2016;30(7):1354–1359. doi:10.1016/j.jdiacomp.2016.05.012
   Web of Science ®Google Scholar
• Cornel JH, Bakris GL, Stevens SR, et al. Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: outcomes from TECOS. Diabetes Care. 2016;39(12):2304–2310. doi:10.2337/dc16-1415
   PubMed Web of Science ®Google Scholar
• Mosenzon O, Leibowitz G, Bhatt DL, et al. Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial. Diabetes Care. 2017;40(1):69–76. doi:10.2337/dc16-0621
   PubMed Web of Science ®Google Scholar
• Esaki H, Tachi T, Goto C, et al. Renoprotective effect of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus. Front Pharmacol. 2017;8:835. doi:10.3389/fphar.2017.00835
   Web of Science ®Google Scholar
• Bae JH, Kim S, Park EG, et al. Effects of dipeptidyl peptidase-4 inhibitors on renal outcomes in patients with type 2 diabetes: a systematic review and meta-analysis. Endocrinol Metab. 2019;34(1):80–92. doi:10.3803/EnM.2019.34.1.80
   Web of Science ®Google Scholar
• Williams DM, Nawaz A, Evans M. Renal outcomes in type 2 diabetes: a review of cardiovascular and renal outcome trials. Diabetes Ther. 2020;11(2):369–386. doi:10.1007/s13300-019-00747-3
   PubMed Web of Science ®Google Scholar
• Morimoto T, Sakuma I, Sakuma M, et al. Randomized evaluation of anagliptin vs sitagliptin on low-density lipoproteiN cholesterol in diabetes (REASON) trial: a 52-week, open-label, randomized clinical trial. Sci Rep. 2019;9(1):8537. doi:10.1038/s41598-019-44885-x
   PubMed Web of Science ®Google Scholar
• Teragawa H, Morimoto T, Fujii Y, et al. Effect of anagliptin versus sitagliptin on inflammatory markers: sub-analysis from the REASON trial. Diabetes Metab Syndr Obes. 2020;13:4993–5001. doi:10.2147/DMSO.S282968
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med. 1999;340(2):115–126. doi:10.1056/NEJM199901143400207
   PubMed Web of Science ®Google Scholar
• Ueda S, Shimabukuro M, Arasaki O, et al. Effect of anagliptin and sitagliptin on low-density lipoprotein cholesterol in type 2 diabetic patients with dyslipidemia and cardiovascular risk: rationale and study design of the REASON trial. Cardiovasc Drugs Ther. 2018;32(1):73–80. doi:10.1007/s10557-018-6776-z
   PubMed Web of Science ®Google Scholar
• Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982–992. doi:10.1053/j.ajkd.2008.12.034
   PubMed Web of Science ®Google Scholar
• Stiller D, Bahn H, August C. Demonstration of glomerular DPP IV activity in kidney diseases. Acta Histochem. 1991;91(1):105–109. doi:10.1016/S0065-1281(11)80302-8
   Web of Science ®Google Scholar
• Sharkovska Y, Reichetzeder C, Alter M, et al. Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy. J Hypertens. 2014;32(11):2211–2223. doi:10.1097/HJH.0000000000000328
   PubMed Web of Science ®Google Scholar
• Kanasaki K. The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin. Clin Sci. 2018;132(4):489–507. doi:10.1042/cs20180031
   Web of Science ®Google Scholar
• Sun AL, Deng JT, Guan GJ, et al. Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney disease. Diab Vasc Dis Res. 2012;9(4):301–308. doi:10.1177/1479164111434318
   PubMed Web of Science ®Google Scholar
• Nakamura K, Oe H, Kihara H, et al. DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study. Cardiovasc Diabetol. 2014;13:110. doi:10.1186/s12933-014-0110-2
   PubMed Web of Science ®Google Scholar
• Kitada M, Tsuda SI, Konishi K, et al. Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner. BMJ Open Diabetes Res Care. 2017;5(1):e000391. doi:10.1136/bmjdrc-2017-000391
   Web of Science ®Google Scholar
• Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321(1):69–79. doi:10.1001/jama.2018.18269
   PubMed Web of Science ®Google Scholar
• Melsom T, Mathisen UD, Ingebretsen OC, et al. Impaired fasting glucose is associated with renal hyperfiltration in the general population. Diabetes Care. 2011;34(7):1546–1551. doi:10.2337/dc11-0235
   Web of Science ®Google Scholar
• Kim YG, Byun J, Yoon D, et al. Renal protective effect of DPP-4 inhibitors in type 2 diabetes mellitus patients: a cohort study. J Diabetes Res. 2016;2016:1423191. doi:10.1155/2016/1423191
   PubMed Web of Science ®Google Scholar
• Sandhu S, Wiebe N, Fried LF, et al. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006;17(7):2006–2016. doi:10.1681/ASN.2006010012
   PubMed Web of Science ®Google Scholar
• Hanratty R, Chonchol M, Havranek EP, et al. Relationship between blood pressure and incident chronic kidney disease in hypertensive patients. Clin J Am Soc Nephrol. 2011;6(11):2605–2611. doi:10.2215/CJN.02240311
   PubMed Web of Science ®Google Scholar